Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

Title
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study
Authors
Keywords
17beta-hydroxysteroid dehydrogenase type 5, AKR1C3, Androgen deprivation therapy, Androgen synthesis, Castration-resistant prostate cancer, Testosterone
Journal
INVESTIGATIONAL NEW DRUGS
Volume 32, Issue 5, Pages 995-1004
Publisher
Springer Nature
Online
2014-04-26
DOI
10.1007/s10637-014-0101-x

Ask authors/readers for more resources

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started